PMID- 35743326
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 12
DP  - 2022 Jun 7
TI  - MDMA for the Treatment of Negative Symptoms in Schizophrenia.
LID - 10.3390/jcm11123255 [doi]
LID - 3255
AB  - The profound economic burden of schizophrenia is due, in part, to the negative 
      symptoms of the disease, which can severely limit daily functioning. There is 
      much debate in the field regarding their measurement and classification and there 
      are no FDA-approved treatments for negative symptoms despite an abundance of 
      research. 3,4-Methylenedioxy methamphetamine (MDMA) is a schedule I substance 
      that has emerged as a novel therapeutic given its ability to enhance social 
      interactions, generate empathy, and induce a state of metaplasticity in the 
      brain. This review provides a rationale for the use of MDMA in the treatment of 
      negative symptoms by reviewing the literature on negative symptoms, their 
      treatment, MDMA, and MDMA-assisted therapy. It reviews recent evidence that 
      supports the safe and potentially effective use of MDMA to treat negative 
      symptoms and concludes with considerations regarding safety and possible 
      mechanisms of action.
FAU - Arnovitz, Mitchell D
AU  - Arnovitz MD
AUID- ORCID: 0000-0002-8322-2965
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Queens, 
      NY 11004, USA.
FAU - Spitzberg, Andrew J
AU  - Spitzberg AJ
AUID- ORCID: 0000-0001-9379-2075
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Queens, 
      NY 11004, USA.
FAU - Davani, Ashkhan J
AU  - Davani AJ
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Queens, 
      NY 11004, USA.
FAU - Vadhan, Nehal P
AU  - Vadhan NP
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Queens, 
      NY 11004, USA.
AD  - Department of Psychiatry, The Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, NY 11549, USA.
AD  - Institute of Behavioral Science, Feinstein Institutes for Medical Research, 
      Manhasset, NY 11030, USA.
FAU - Holland, Julie
AU  - Holland J
AD  - Private Practice, New York City, NY 10016, USA.
FAU - Kane, John M
AU  - Kane JM
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Queens, 
      NY 11004, USA.
AD  - Department of Psychiatry, The Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, NY 11549, USA.
AD  - Institute of Behavioral Science, Feinstein Institutes for Medical Research, 
      Manhasset, NY 11030, USA.
FAU - Michaels, Timothy I
AU  - Michaels TI
AUID- ORCID: 0000-0002-3048-6860
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Queens, 
      NY 11004, USA.
AD  - Department of Psychiatry, The Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, NY 11549, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220607
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9225098
OTO - NOTNLM
OT  - MDMA
OT  - negative symptoms
OT  - psychedelic-assisted therapy
OT  - psychosis
OT  - schizophrenia
COIS- J.M.K. has received honoraria for lectures or consulting fees from Alkermes, 
      Allergan, Boehringer Ingelheim, Cerevel, Click Therapeutics, Dainippon Sumitomo, 
      HLS, Indivior, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharmaceuticals, 
      Lundbeck, Merck, Minerva, Neumora, Neurocrine, Newron, Novartis, Otsuka, Reviva, 
      Roche, Saladax Biomedical, Sunovion, Takeda, and Teva. He is a shareholder of The 
      Vanguard Research Group, and LB Pharma NPV is a paid research consultant to 
      Sunnyside/Cutback Coach, LLC, an online alcohol moderation platform. J.H. is on 
      the scientific advisory board for Apotheca, CB1 Capital, MycoMedica, Palo Santo, 
      and Tactogen. She is a Medical Advisor for Cardea and MAPS.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/25 06:01
PMCR- 2022/06/07
CRDT- 2022/06/24 01:24
PHST- 2022/05/17 00:00 [received]
PHST- 2022/05/31 00:00 [revised]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/06/24 01:24 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/25 06:01 [medline]
PHST- 2022/06/07 00:00 [pmc-release]
AID - jcm11123255 [pii]
AID - jcm-11-03255 [pii]
AID - 10.3390/jcm11123255 [doi]
PST - epublish
SO  - J Clin Med. 2022 Jun 7;11(12):3255. doi: 10.3390/jcm11123255.